{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:25:39Z","timestamp":1759623939066,"version":"build-2065373602"},"reference-count":42,"publisher":"BMFH Press","issue":"4","funder":[{"name":"each participating facility\u2019s own funds"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.12938\/bmfh.2025-015","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T18:06:42Z","timestamp":1746554802000},"page":"272-278","source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic combination therapy for the induction and maintenance of remission in patients with ulcerative colitis"],"prefix":"10.12938","volume":"44","author":[{"given":"Yuriko","family":"NISHIKAWA","sequence":"first","affiliation":[{"name":"Department of Microbiota Research, Juntendo University Graduate School of              Medicine, 3-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"OHKUSA","sequence":"additional","affiliation":[{"name":"Department of Microbiota Research, Juntendo University Graduate School of              Medicine, 3-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan"},{"name":"Department of Gastroenterology and Hepatology, The Jikei University Kashiwa              Hospital, Kashiwa, Chiba 277-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyoshi","family":"SHIBUYA","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Juntendo University School of Medicine,              Tokyo 113-8421, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"OSADA","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Juntendo University School of Medicine,              Tokyo 113-8421, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"UCHIYAMA","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, The Jikei University Kashiwa              Hospital, Kashiwa, Chiba 277-8567, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"SATO","sequence":"additional","affiliation":[{"name":"Department of Microbiota Research, Juntendo University Graduate School of              Medicine, 3-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5076","reference":[{"doi-asserted-by":"crossref","unstructured":"1. Gilliland              A, Chan              JJ, De Wolfe              TJ, Yang              H, Vallance              BA. 2024.            Pathobionts in inflammatory bowel disease: origins, underlying            mechanisms, and implications for clinical care.            Gastroenterology 166:            44\u201358.","key":"1","DOI":"10.1053\/j.gastro.2023.09.019"},{"doi-asserted-by":"crossref","unstructured":"2. Shen              ZH, Zhu              CX, Quan              YS, Yang              ZY, Wu              S, Luo              WW, Tan              B, Wang              XY. 2018.            Relationship between intestinal microbiota and ulcerative colitis:            mechanisms and clinical application of probiotics and fecal microbiota            transplantation. World J Gastroenterol 24: 5\u201314.","key":"2","DOI":"10.3748\/wjg.v24.i1.5"},{"doi-asserted-by":"crossref","unstructured":"3. Singh              S, Allegretti              JR, Siddique              SM, Terdiman              JP. 2020.            AGA Technical review on the management of moderate to severe ulcerative            colitis. Gastroenterology 158:          1465\u20131496.e17.","key":"3","DOI":"10.1053\/j.gastro.2020.01.007"},{"doi-asserted-by":"crossref","unstructured":"4. Wetwittayakhlang              P, Gonczi              L, Lakatos              L, Kurti              Z, Golovics              P, Pandur              T, David              G, Erdelyi              Z, Szita              I, Lakatos              PL. 2023.            Long-term colectomy rates of ulcerative colitis over 40 years of            different therapeutic eras\u2014results from a western Hungarian population-based inception            cohort between 1977 and 2020. J Crohns Colitis 17: 712\u2013721.","key":"4","DOI":"10.1093\/ecco-jcc\/jjac188"},{"doi-asserted-by":"crossref","unstructured":"5. Rosenbaum              M. 1983.            Ulcerative colitis.            Psychosomatics 24: 515\u2013519,            522\u2013525, 528\u2013529.","key":"5","DOI":"10.1016\/S0033-3182(83)73183-X"},{"doi-asserted-by":"crossref","unstructured":"6. Faye              AS, Allin              KH, Iversen              AT, Agrawal              M, Faith              J, Colombel              JF, Jess              T. 2023.            Antibiotic use as a risk factor for inflammatory bowel disease across the            ages: a population-based cohort study. Gut 72: 663\u2013670.","key":"6","DOI":"10.1136\/gutjnl-2022-327845"},{"doi-asserted-by":"crossref","unstructured":"7. Barnes              EL, Desai              A, Kochhar              GS. 2023.            The comparative effectiveness of ciprofloxacin and metronidazole for an            initial episode of pouchitis: a propensity-matched study. Am J            Gastroenterol 118: 1989\u20131996.","key":"7","DOI":"10.14309\/ajg.0000000000002412"},{"doi-asserted-by":"crossref","unstructured":"8. Barnes              EL, Agrawal              M, Syal              G,                Ananthakrishnan              AN, Cohen              BL, Haydek              JP, Al Kazzi              ES,                Eisenstein              S, Hashash              JG, Sultan              SS, et            al. AGA Clinical Guidelines Committee. AGA Clinical practice guideline on the management of            pouchitis and inflammatory pouch disorders.            Gastroenterology 166:            59\u201385.","key":"8","DOI":"10.1053\/j.gastro.2023.10.015"},{"doi-asserted-by":"crossref","unstructured":"9. Parigi              TL, Vieujean              S, Paridaens              K, Dalgaard              K,                Peyrin-Biroulet              L, Danese              S. 2023.            Efficacy, safety, and concerns on microbiota modulation, antibiotics,            probiotics, and fecal microbial transplant for inflammatory bowel disease and other            gastrointestinal conditions: results from an international survey.            Microorganisms 11: 2826.","key":"9","DOI":"10.3390\/microorganisms11112806"},{"doi-asserted-by":"crossref","unstructured":"10. Eindor-Abarbanel              A, Healey              GR, Jacobson              K, Stolfi              C. 2021.            Therapeutic advances in gut microbiome modulation in patients with            inflammatory bowel disease from pediatrics to adulthood. Int J            Mol Sci 22: 12506.","key":"10","DOI":"10.3390\/ijms222212506"},{"doi-asserted-by":"crossref","unstructured":"11. Wang              SL, Wang              ZR, Yang              CQ. 2012.            Meta-analysis of broad-spectrum antibiotic therapy in patients with            active inflammatory bowel disease. Exp Ther Med 4: 1051\u20131056.","key":"11","DOI":"10.3892\/etm.2012.718"},{"doi-asserted-by":"crossref","unstructured":"12. Khan              KJ, Ullman              TA, Ford              AC, Abreu              MT, Abadir              A, Marshall              JK, Talley              NJ, Moayyedi              P. 2011.            Antibiotic therapy in inflammatory bowel disease: a systematic review and            meta-analysis. Am J Gastroenterol 106:            661\u2013673.","key":"12","DOI":"10.1038\/ajg.2011.72"},{"doi-asserted-by":"crossref","unstructured":"13. Gordon              M, Sinopoulou              V,                Grafton-Clarke              C, Akobeng              AK. 2022.            Antibiotics for the induction and maintenance of remission in ulcerative            colitis. Cochrane Database Syst Rev 5:            CD013743.","key":"13","DOI":"10.1002\/14651858.CD013743.pub2"},{"doi-asserted-by":"crossref","unstructured":"14. Oka              A, Sartor              RB. 2020.            Microbial-based and microbial-targeted therapies for inflammatory bowel            diseases. Dig Dis Sci 65:            757\u2013788.","key":"14","DOI":"10.1007\/s10620-020-06090-z"},{"doi-asserted-by":"crossref","unstructured":"15. Ohkusa              T, Nomura              T, Terai              T, Miwa              H, Kobayashi              O, Hojo              M, Takei              Y, Ogihara              T, Hirai              S, Okayasu              I, et            al. 2005. Effectiveness of antibiotic            combination therapy in patients with active ulcerative colitis: a randomized, controlled            pilot trial with long-term follow-up. Scand J            Gastroenterol 40: 1334\u20131342.","key":"15","DOI":"10.1080\/00365520510023648"},{"doi-asserted-by":"crossref","unstructured":"16. Ohkusa              T, Kato              K, Terao              S, Chiba              T, Mabe              K, Murakami              K, Mizokami              Y, Sugiyama              T, Yanaka              A, Takeuchi              Y, et            al. Japan UC Antibiotic Therapy Study            Group 2010. Newly developed antibiotic            combination therapy for ulcerative colitis: a double-blind placebo-controlled            multicenter trial. Am J Gastroenterol 105: 1820\u20131829.","key":"16","DOI":"10.1038\/ajg.2010.84"},{"doi-asserted-by":"crossref","unstructured":"17. Koido              S, Ohkusa              T, Kajiura              T, Shinozaki              J, Suzuki              M, Saito              K, Takakura              K, Tsukinaga              S, Odahara              S, Yukawa              T, et            al. 2014. Long-term alteration of            intestinal microbiota in patients with ulcerative colitis by antibiotic combination            therapy. PLoS One 9:            e86702.","key":"17","DOI":"10.1371\/journal.pone.0086702"},{"doi-asserted-by":"crossref","unstructured":"18. Nishikawa              Y, Sato              N, Tsukinaga              S, Uchiyama              K, Koido              S, Ishikawa              D, Ohkusa              T. 2021.            Long-term outcomes of antibiotic combination therapy for ulcerative            colitis. Ther Adv Chronic Dis 12:            20406223211028790.","key":"18","DOI":"10.1177\/20406223211028790"},{"doi-asserted-by":"crossref","unstructured":"19. Ishikawa              D, Sasaki              T, Osada              T,                Kuwahara-Arai              K, Haga              K, Shibuya              T, Hiramatsu              K, Watanabe              S. 2017.            Changes in intestinal microbiota following combination therapy with fecal            microbial transplantation and antibiotics for ulcerative colitis.            Inflamm Bowel Dis 23:            116\u2013125.","key":"19","DOI":"10.1097\/MIB.0000000000000975"},{"doi-asserted-by":"crossref","unstructured":"20. Breton              J, Kastl              A, Hoffmann              N, Rogers              R, Grossman              AB, Mamula              P, Kelsen              JR,                Baldassano              RN, Albenberg              L. 2019.            Efficacy of combination antibiotic therapy for refractory pediatric            inflammatory bowel disease. Inflamm Bowel Dis 25: 1586\u20131593.","key":"20","DOI":"10.1093\/ibd\/izz006"},{"doi-asserted-by":"crossref","unstructured":"21. Burke              DA, Axon              AT, Clayden              SA, Dixon              MF, Johnston              D, Lacey              RW. 1990.            The efficacy of tobramycin in the treatment of ulcerative            colitis. Aliment Pharmacol Ther 4:            123\u2013129.","key":"21","DOI":"10.1111\/j.1365-2036.1990.tb00456.x"},{"doi-asserted-by":"publisher","unstructured":"22. Turunen              UM, F\u00e4rkkil\u00e4              MA, Hakala              K, Sepp\u00e4l\u00e4              K, Sivonen              A, Ogren              M, Vuoristo              M, Valtonen              VV, Miettinen              TA. 1998.            Long-term treatment of ulcerative colitis with ciprofloxacin: a            prospective, double-blind, placebo-controlled study.            Gastroenterology 115:            1072\u20131078.","key":"22","DOI":"10.1016\/S0016-5085(98)70076-9"},{"doi-asserted-by":"crossref","unstructured":"23. Mantzaris              GJ, Petraki              K, Archavlis              E, Amberiadis              P, Kourtessas              D, Christidou              A,                Triantafyllou              G. 2001.            A prospective randomized controlled trial of intravenous ciprofloxacin as            an adjunct to corticosteroids in acute, severe ulcerative colitis.            Scand J Gastroenterol 36:            971\u2013974.","key":"23","DOI":"10.1080\/003655201750305503"},{"doi-asserted-by":"publisher","unstructured":"24. Chapman              RW, Selby              WS, Jewell              DP. 1986.            Controlled trial of intravenous metronidazole as an adjunct to            corticosteroids in severe ulcerative colitis.            Gut 27: 1210\u20131212.","key":"24","DOI":"10.1136\/gut.27.10.1210"},{"doi-asserted-by":"crossref","unstructured":"25. Dami\u00e3o              AOMC, de                Azevedo              MFC, Carlos              AS, Wada              MY, Silva              TVM, Feitosa              FC. 2019.            Conventional therapy for moderate to severe inflammatory bowel disease: a            systematic literature review. World J            Gastroenterol 25: 1142\u20131157.","key":"25","DOI":"10.3748\/wjg.v25.i9.1142"},{"doi-asserted-by":"crossref","unstructured":"26. Komaki              Y, Komaki              F, Ido              A, Sakuraba              A. 2016.            Efficacy and safety of tacrolimus therapy for active ulcerative colitis;            a systematic review and meta-analysis. J Crohns            Colitis 10: 484\u2013494.","key":"26","DOI":"10.1093\/ecco-jcc\/jjv221"},{"doi-asserted-by":"crossref","unstructured":"27. Narula              N, Fine              M, Colombel              JF, Marshall              JK, Reinisch              W. 2015.            Systematic review: sequential rescue therapy in severe ulcerative            colitis: do the benefits outweigh the risks? Inflamm Bowel            Dis 21: 1683\u20131694.","key":"27","DOI":"10.1097\/MIB.0000000000000350"},{"doi-asserted-by":"publisher","unstructured":"28. D\u2019Haens              G, Lemmens              L, Geboes              K, Vandeputte              L, Van Acker              F, Mortelmans              L, Peeters              M, Vermeire              S, Penninckx              F, Nevens              F, et            al. 2001. Intravenous cyclosporine            versus intravenous corticosteroids as single therapy for severe attacks of ulcerative            colitis. Gastroenterology 120:            1323\u20131329.","key":"28","DOI":"10.1053\/gast.2001.23983"},{"doi-asserted-by":"crossref","unstructured":"29. Lichtiger              S, Present              DH, Kornbluth              A, Gelernt              I, Bauer              J, Galler              G, Michelassi              F, Hanauer              S. 1994.            Cyclosporine in severe ulcerative colitis refractory to steroid            therapy. N Engl J Med 330:            1841\u20131845.","key":"29","DOI":"10.1056\/NEJM199406303302601"},{"doi-asserted-by":"crossref","unstructured":"30. Sands              BE, Sandborn              WJ,                Panaccione              R, O\u2019Brien              CD, Zhang              H, Johanns              J, Adedokun              OJ, Li              K,                Peyrin-Biroulet              L, Van Assche              G, et            al. UNIFI Study Group 2019.            Ustekinumab as induction and maintenance therapy for ulcerative            colitis. N Engl J Med 381:            1201\u20131214.","key":"30","DOI":"10.1056\/NEJMoa1900750"},{"doi-asserted-by":"crossref","unstructured":"31. Peyrin-Biroulet              L, L\u00e9mann              M. 2011.            Review article: remission rates achievable by current therapies for            inflammatory bowel disease. Aliment Pharmacol            Ther 33: 870\u2013879.","key":"31","DOI":"10.1111\/j.1365-2036.2011.04599.x"},{"doi-asserted-by":"crossref","unstructured":"32. Rutgeerts              P, Sandborn              WJ, Feagan              BG, Reinisch              W, Olson              A, Johanns              J, Travers              S,                Rachmilewitz              D, Hanauer              SB,                Lichtenstein              GR, et            al. 2005. Infliximab for induction and            maintenance therapy for ulcerative colitis. N Engl J            Med 353: 2462\u20132476.","key":"32","DOI":"10.1056\/NEJMoa050516"},{"doi-asserted-by":"publisher","unstructured":"33. Sandborn              WJ, Feagan              BG, Marano              C, Zhang              H, Strauss              R, Johanns              J, Adedokun              OJ, Guzzo              C, Colombel              JF, Reinisch              W, et            al. PURSUIT-Maintenance Study            Group 2014. Subcutaneous golimumab maintains            clinical response in patients with moderate-to-severe ulcerative          colitis. Gastroenterology 146:            96\u2013109.e1.","key":"33","DOI":"10.1053\/j.gastro.2013.06.010"},{"doi-asserted-by":"publisher","unstructured":"34. Sandborn              WJ, van                Assche              G, Reinisch              W, Colombel              JF, D\u2019Haens              G, Wolf              DC, Kron              M, Tighe              MB, Lazar              A, Thakkar              RB. 2012.            Adalimumab induces and maintains clinical remission in patients with            moderate-to-severe ulcerative colitis.          Gastroenterology 142: 257\u201365.e1,            3.","key":"34","DOI":"10.1053\/j.gastro.2011.10.032"},{"doi-asserted-by":"publisher","unstructured":"35. Kirchgesner              J, Lemaitre              M, Carrat              F, Zureik              M, Carbonnel              F, Dray-Spira              R. 2018.            Risk of serious and opportunistic infections associated with treatment of            inflammatory bowel diseases. Gastroenterology 155: 337\u2013346.e10.","key":"35","DOI":"10.1053\/j.gastro.2018.04.012"},{"doi-asserted-by":"crossref","unstructured":"36. Chupin              A, Perduca              V, Meyer              A, Bellanger              C, Carbonnel              F, Dong              C. 2020.            Systematic review with meta-analysis: comparative risk of lymphoma with            anti-tumour necrosis factor agents and\/or thiopurines in patients with inflammatory            bowel disease. Aliment Pharmacol Ther 52: 1289\u20131297.","key":"36","DOI":"10.1111\/apt.16050"},{"doi-asserted-by":"crossref","unstructured":"37. Dolovich              C, Bernstein              CN, Singh              H, Nugent              Z, Tennakoon              A, Shafer              LA, Marrie              RA, Sareen              J, Targownik              LE. 2021.            Anxiety and depression leads to anti-tumor necrosis factor            discontinuation in inflammatory bowel disease. Clin            Gastroenterol Hepatol 19:          1200\u20131208.e1.","key":"37","DOI":"10.1016\/j.cgh.2020.07.013"},{"doi-asserted-by":"crossref","unstructured":"38. Sandborn              WJ, Feagan              BG, Hanauer              S, Vermeire              S, Ghosh              S, Liu              WJ, Petersen              A, Charles              L, Huang              V, Usiskin              K, et            al. 2021. Long-term efficacy and safety            of ozanimod in moderately to severely active ulcerative colitis: results from the            open-label extension of the randomized, phase 2 TOUCHSTONE study.            J Crohns Colitis 15:            1120\u20131129.","key":"38","DOI":"10.1093\/ecco-jcc\/jjab012"},{"doi-asserted-by":"crossref","unstructured":"39. Zhao              H, Zhang              W, Cheng              D, You              L, Huang              Y, Lu              Y. 2022.            Investigating dysbiosis and microbial treatment strategies in            inflammatory bowel disease based on two modified Koch\u2019s postulates.            Front Med (Lausanne) 9: 1023896.","key":"39","DOI":"10.3389\/fmed.2022.1023896"},{"doi-asserted-by":"publisher","unstructured":"40. Kostic              AD, Xavier              RJ, Gevers              D. 2014.            The microbiome in inflammatory bowel disease: current status and the            future ahead. Gastroenterology 146:            1489\u20131499.","key":"40","DOI":"10.1053\/j.gastro.2014.02.009"},{"doi-asserted-by":"crossref","unstructured":"41. Zhang              SL, Wang              SN, Miao              CY, Reitzel              AM, Law              KM. 2017.            Influence of microbiota on intestinal immune system in ulcerative colitis            and its intervention. Front Immunol 8:            1674.","key":"41","DOI":"10.3389\/fimmu.2017.01674"},{"doi-asserted-by":"crossref","unstructured":"42. Ohkusa              T, Kato              K, Sekizuka              T, Sugiyama              T, Sato              N, Kuroda              M. 2024.            Comparison of the gut microbiota of patients who improve with antibiotic            combination therapy for ulcerative colitis and those who do not: investigation by fecal            metagenomic analyses. Nutrients 16:            3500.","key":"42","DOI":"10.3390\/nu16203500"}],"container-title":["Bioscience of Microbiota, Food and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bmfh\/44\/4\/44_2025-015\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:39:06Z","timestamp":1759552746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bmfh\/44\/4\/44_2025-015\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.12938\/bmfh.2025-015","relation":{},"ISSN":["2186-3342"],"issn-type":[{"type":"electronic","value":"2186-3342"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"2025-015"}}